Yuhan Corporation has partnered with Novartis Korea to distribute, sell, and promote the chronic spontaneous urticaria treatment 'Rapsido' (active ingredient: remibrutinib) in South Korea. The two companies announced the strategic partnership agreement on September 7.
Under the agreement, Yuhan Corporation will handle domestic distribution, while Novartis Korea will focus on promotional activities in general hospitals, and Yuhan will target clinics and private practices.
Rapsido is the first oral Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of chronic spontaneous urticaria. It received domestic approval in April for adult patients whose symptoms are inadequately controlled by H1 antihistamines.
Chronic spontaneous urticaria is a condition characterized by the activation of mast cells, leading to the release of inflammatory mediators such as histamine, resulting in hives, angioedema, and itching. While existing antihistamines work by blocking the action of released histamine on receptors, Rapsido operates by inhibiting BTK, which is involved in the activation of mast cells and basophils, thereby reducing the release of inflammatory mediators.
The domestic approval was based on the results of global Phase 3 clinical trials 'REMIX-1' and 'REMIX-2'. In these trials, Rapsido significantly improved the weekly urticaria activity score (UAS7) compared to placebo at 12 weeks, with effects maintained up to 24 weeks.
The 52-week analysis showed improvements in itching and hives symptoms from the first week of treatment, with therapeutic effects lasting up to 52 weeks. The safety profile over 52 weeks was generally consistent with the 24-week analysis.
The two companies plan to expand the distribution and sales of Rapsido through this partnership and enhance treatment accessibility for patients with chronic spontaneous urticaria.
Yuhan Corporation CEO Cho Wook-je stated, "Leveraging our sales and marketing capabilities and nationwide distribution network, we aim to effectively communicate the value of Rapsido to healthcare professionals and patients, contributing to the improvement of treatment environments."
Meanwhile, Yuhan Corporation's active pharmaceutical ingredient (API) business is progressing well. On September 1, the company announced a supply contract worth 130 billion won with a global pharmaceutical company, although the identity of the partner was not disclosed. The contract amount is 131,074,440,640 won.
This year, Yuhan Corporation has confirmed a total of three API supply contracts through public announcements, with a total contract value of approximately 397 billion won.
Under the agreement, Yuhan Corporation will handle domestic distribution, while Novartis Korea will focus on promotional activities in general hospitals, and Yuhan will target clinics and private practices.
Rapsido is the first oral Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of chronic spontaneous urticaria. It received domestic approval in April for adult patients whose symptoms are inadequately controlled by H1 antihistamines.
Chronic spontaneous urticaria is a condition characterized by the activation of mast cells, leading to the release of inflammatory mediators such as histamine, resulting in hives, angioedema, and itching. While existing antihistamines work by blocking the action of released histamine on receptors, Rapsido operates by inhibiting BTK, which is involved in the activation of mast cells and basophils, thereby reducing the release of inflammatory mediators.
The domestic approval was based on the results of global Phase 3 clinical trials 'REMIX-1' and 'REMIX-2'. In these trials, Rapsido significantly improved the weekly urticaria activity score (UAS7) compared to placebo at 12 weeks, with effects maintained up to 24 weeks.
The 52-week analysis showed improvements in itching and hives symptoms from the first week of treatment, with therapeutic effects lasting up to 52 weeks. The safety profile over 52 weeks was generally consistent with the 24-week analysis.
The two companies plan to expand the distribution and sales of Rapsido through this partnership and enhance treatment accessibility for patients with chronic spontaneous urticaria.
Yuhan Corporation CEO Cho Wook-je stated, "Leveraging our sales and marketing capabilities and nationwide distribution network, we aim to effectively communicate the value of Rapsido to healthcare professionals and patients, contributing to the improvement of treatment environments."
Meanwhile, Yuhan Corporation's active pharmaceutical ingredient (API) business is progressing well. On September 1, the company announced a supply contract worth 130 billion won with a global pharmaceutical company, although the identity of the partner was not disclosed. The contract amount is 131,074,440,640 won.
This year, Yuhan Corporation has confirmed a total of three API supply contracts through public announcements, with a total contract value of approximately 397 billion won.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.